Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics, Inc. (ARQT) from its SEC filings: 2025 revenue $376.1 million (+91% vs the year before), net margin -4%, free cash flow -$6.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $376.1 million |
| Revenue growth | +91% |
| Net income | -$16.1 million |
| Net margin | -4.3% |
| Free cash flow | -$6.3 million |
| Diluted EPS | $-0.13 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +59% |
| Cash | $34.1 million |
| Long-term debt | $102.0 million |
| Share count, 1 year | +5% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.